Mechelen, Belgium and Bristol, United Kingdom; 15 February 2007 - Galapagos NV (Euronext & LSE: GLPG) and the University of Bristol today announced a new drug discovery collaboration in the field of cancer research. Galapagos’ service division BioFocus DPI will provide lead optimization services for a University of Bristol research program focusing on destroying cancer cells. Total contract value for Galapagos exceeds EUR 2 million in research fees over two years.
